Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $1.9 million.

  • Immunome's Change in Account Payables rose 188.76% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 663.36%. This contributed to the annual value of $9.5 million for FY2024, which is 1666.78% up from last year.
  • Immunome's Change in Account Payables amounted to $1.9 million in Q3 2025, which was up 137.81% from -$4.9 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Change in Account Payables peaked at $9.3 million during Q4 2024, and registered a low of -$4.9 million during Q2 2025.
  • Over the past 3 years, Immunome's median Change in Account Payables value was -$32,000 (recorded in 2024), while the average stood at $184,636.
  • As far as peak fluctuations go, Immunome's Change in Account Payables spiked by 1,465.24% in 2024, and later plummeted by 15,362.50% in 2025.
  • Quarterly analysis of 3 years shows Immunome's Change in Account Payables stood at -$679,000 in 2023, then soared by 1,465.24% to $9.3 million in 2024, then skyrocketed by 188.76% to $1.9 million in 2025.
  • Its Change in Account Payables stands at $1.9 million for Q3 2025, versus -$4.9 million for Q2 2025 and -$3.8 million for Q1 2025.